BRCA1 and melanoma: In vitro studies of niraparib treatment on melanoma cell lines, MM425X, (harbouring mutations in BRCA1 and ARID1B), MM390 (harbouring mutation in CHD2) and MM507X cells (no detectable HR mutations) at concentrations between 1 um and 60 um in cultures showed decreased survival and induction of apoptosis in both of the HR-DDR positive samples [23].